Recursion Pharmaceuticals, Inc.

Overview

"How the company got here": "Recursion Pharmaceuticals was founded in 2013 by a team of scientists and technologists who believed that artificial intelligence (AI) and automated experiments could significantly speed up the slow and expensive process of discovering new drugs. The traditional method of drug discovery can take over a decade and billions of dollars, with a high rate of failure. The company's founders aimed to industrialize drug discovery by using technology to decode biology and chemistry. Recursion's early focus was on rare diseases, and they developed a platform that uses automated labs, high-resolution cell imaging, and machine learning to identify potential drug candidates. This innovative approach attracted significant investment, and Recursion went public on the NASDAQ in 2021.", "What it actually does": "Recursion Pharmaceuticals uses a sophisticated technology platform, known as the Recursion OS, to discover and develop new medicines. This platform combines automated laboratory experiments, advanced imaging, and artificial intelligence (AI) to analyze vast amounts of biological data. By doing so, Recursion aims to identify potential drug candidates much faster and more efficiently than traditional methods. The company's ultimate goal is to industrialize the drug discovery process, making it more predictable and less costly, to bring new treatments to patients more quickly.", "Drug Discovery Platform": "Recursion's core business is its AI-driven drug discovery platform, called the Recursion OS. This platform uses automated labs to conduct millions of experiments weekly, where cells are imaged after genetic or chemical changes. AI algorithms then analyze these images to identify patterns that might indicate a potential drug's effectiveness. This data-driven approach allows Recursion to explore a vast number of biological relationships and identify novel drug candidates that might be missed by human researchers. The company generates revenue through partnerships with larger pharmaceutical companies, licensing agreements, and by developing its own internal drug pipeline.", "Internal Drug Pipeline": "Recursion also develops its own potential medicines through its internal drug pipeline, focusing on diseases with high unmet medical needs, particularly in oncology (cancer) and rare diseases. The company has several drug candidates in various stages of clinical trials, meaning they are being tested in humans to assess safety and effectiveness. For example, REC-4881 is being developed for familial adenomatous polyposis, a rare genetic disorder, and REC-617 is being investigated for advanced solid tumors. Success in these clinical trials could lead to regulatory approval and future revenue from drug sales, though this is a long and uncertain process.", "What management is betting on now": "Recursion's management is focused on advancing its AI-driven drug discovery platform and expanding its internal pipeline of potential medicines. They are investing heavily in their proprietary technology, including their supercomputer infrastructure, to enhance their ability to analyze biological data and identify promising drug candidates. A key strategy is to leverage partnerships with larger pharmaceutical companies, which provide funding and expertise, while also continuing to develop their own drug programs. The company is prioritizing its most promising drug candidates and aims to improve the efficiency and success rate of drug development, ultimately seeking to become a leader in the industrialization of drug discovery."